Strategic research partnerships bring together knowledge, expertise and technologies, allowing advancements in our understanding of diseases and therapeutics that would not be possible in isolation.
Optibrium and PostEra integrate AI drug discovery solutions
Optibrium and PostEra plan to integrate Optibrium’s StarDrop platform with PostEra’s Manifold software.
StarDrop’s drug discovery software includes de novo compound design, optimisation, and data analysis, and with the integration of Manifold’s retrosynthesis machine learning (ML) capabilities, users can also identify the best scalable synthetic routes.
Manifold is a retrosynthesis software that uses ML algorithms to select the best scalable routes for compound synthesis from accessible building blocks. To streamline project timelines, starting materials which are available to purchase can be identified through dynamic connections to contract research organisations, globally.
Aitia and UCB focus on drug targets for Huntington’s Disease
UCB and Aitia have agreed a collaboration focused on the discovery and validation of novel drug targets and drug candidates for Huntingdon’s disease.
The collaboration seeks to validate novel drug targets that are causally linked to clinical endpoints in Huntington’s disease.
It will combine the use of novel Huntington’s disease drug targets from Aitia’s Gemini Digital Twins with UCB’s expertise in drug research and preclinical model systems in neurodegeneration, with the aim to accelerate the discovery of new therapies for people living with Huntington’s disease.
It is estimated that Huntington’s disease affects approximately 1 in 10,000 people worldwide and currently there is no cure and treatment options are limited.
Oxford Drug Design and PhoreMost advance novel cancer therapeutics
Oxford Drug Design has been engaged by PhoreMost to accelerate a targeted protein degradation discovery programme for novel cancer therapeutics.
The project uses Oxford Drug Design’s artificial intelligence (AI) computational platform consisting of multiple computational drug discovery capabilities for both ligand- and structure-based design, together with PhoreMost’s SITESEEKER phenotypic screening platform and PROTEINi libraries.
Oxford Drug Design has analysed the structural biology data and known binding compounds to identify and advance the development of novel, drug-like, compounds for onward optimisation.
AI and machine learning technologies offer the prospect of analysing vast datasets and developing viable drugs in a more cost-efficient way.
CHARM Therapeutics and Bristol Myers Squibb accelerate small molecule programmes
CHARM Therapeutics and Bristol Myers Squibb have agreed a collaboration for the identification and optimisation of compounds against Bristol Myers Squibb selected targets.
CHARM will use DragonFold, its deep learning platform that identifies novel molecules through protein-ligand co-folding, to discover novel compounds.
Under the terms of the agreement, CHARM is responsible for the early discovery of compounds against targets of interest to Bristol Myers Squibb, who has the option to license and develop compounds from the collaboration.
In addition to upfront investment in CHARM, the company is eligible to receive additional payments should Bristol Myers Squibb develop any of the compounds.
